Neuroprotection and acute spinal cord injury: a reappraisal.

NeuroRx 2004 Jan;1(1):80-100

Spinal Cord and Brain Injury Research Center, University of Kentucky Chandler Medical Center, Lexington, Kentucky 40536, USA.

It has long been recognized that much of the post-traumatic degeneration of the spinal cord following injury is caused by a multi-factorial secondary injury process that occurs during the first minutes, hours, and days after spinal cord injury (SCI). A key biochemical event in that process is reactive oxygen-induced lipid peroxidation (LP). In 1990 the results of the Second National Acute Spinal Cord Injury Study (NASCIS II) were published, which showed that the administration of a high-dose regimen of the glucocorticoid steroid methylprednisolone (MP), which had been previously shown to inhibit post-traumatic LP in animal models of SCI, could improve neurological recovery in spinal-cord-injured humans. This resulted in the registration of high-dose MP for acute SCI in several countries, although not in the U.S. Nevertheless, this treatment quickly became the standard of care for acute SCI since the drug was already on the U.S. market for many other indications. Subsequently, it was demonstrated that the non-glucocorticoid 21-aminosteroid tirilazad could duplicate the antioxidant neuroprotective efficacy of MP in SCI models, and evidence of human efficacy was obtained in a third NASCIS trial (NASCIS III). In recent years, the use of high-dose MP in acute SCI has become controversial largely on the basis of the risk of serious adverse effects versus what is perceived to be on average a modest neurological benefit. The opiate receptor antagonist naloxone was also tested in NASCIS II based upon the demonstration of its beneficial effects in SCI models. Although it did not a significant overall effect, some evidence of efficacy was seen in incomplete (i.e., paretic) patients. The monosialoganglioside GM1 has also been examined in a recently completed clinical trial in which the patients first received high-dose MP treatment. However, GM1 failed to show any evidence of a significant enhancement in the extent of neurological recovery over the level afforded by MP therapy alone. The present paper reviews the past development of MP, naloxone, tirilazad, and GM1 for acute SCI, the ongoing MP-SCI controversy, identifies the regulatory complications involved in future SCI drug development, and suggests some promising neuroprotective approaches that could either replace or be used in combination with high-dose MP.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC534914PMC
http://dx.doi.org/10.1602/neurorx.1.1.80DOI Listing
January 2004
4 Reads

Publication Analysis

Top Keywords

cord injury
16
spinal cord
16
acute sci
16
sci
9
neurological recovery
8
sci models
8
models evidence
8
high-dose acute
8
sci drug
8
acute spinal
8
injury
5
acute
5
high-dose
5
controversial basis
4
basis risk
4
serious adverse
4
versus perceived
4
risk serious
4
adverse effects
4
effects versus
4

Altmetric Statistics

References

(Supplied by CrossRef)

DK Anderson et al.
Ann Emerg Med 1993

ED Hall et al.
1996

ED Hall et al.
Free Radic Biol Med 1989

CH Tator et al.
J Neurosurg 1991

AI Faden et al.
Adv Neurol 1997

AI Faden et al.
Trends Pharmacol Sci 1992

JM Braughler et al.
Free Radic Biol Med 1989

ED Hall et al.
Res Publ Assoc Res Nerv Ment Dis 1993

AI Faden et al.
Adv Biochem Psychopharmacol 1981

HJ Reulen et al.
1972

MB Bracken et al.
JAMA 1984

Similar Publications